for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Addex Therapeutics Ltd

ADXN.S

Latest Trade

1.75CHF

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.43

 - 

2.52

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.75
Open
--
Volume
--
3M AVG Volume
0.55
Today's High
--
Today's Low
--
52 Week High
2.52
52 Week Low
1.43
Shares Out (MIL)
26.49
Market Cap (MIL)
57.49
Forward P/E
-4.13
Dividend (Yield %)
--

Latest Developments

More

Addex Therapeutics H1 Net Profit Swings To Loss Of CHF 7.5 Mln

Addex Therapeutics Increases Issued Share Capital

Addex Therapeutics FY Net Loss At CHF 1.6 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Addex Therapeutics Ltd

Addex Therapeutics Ltd is a Switzerland-based company, that discovers and develops a class of small molecule drugs, allosteric modulators. Its two products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or is being developed by the Company to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by its partner Janssen Pharmaceuticals Inc. to treat schizophrenia. It also is advancing several preclinical programs, including GABA-BR PAM for pain, overactive bladder and other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression, and FSHR/LHR NAM for sex hormone dependent tumors and reproductive system disorders. In addition, it has discovery programs to identify allosteric modulators of receptor tyrosine kinase superfamily

Industry

Biotechnology & Drugs

Contact Info

Chemin des Aulx 12, Case Postale 68

+41.22.8841555

https://www.addextherapeutics.com/

Executive Leadership

Vincent Lawton

Chairman of the Board of Directors

Tim Dyer

Chief Executive Officer, Member of the Executive Board, Member of the Board of Directors

Roger G. Mills

Member of the Executive Board, Chief Medical Officer, Member of the Board of Directors

Robert Luetjens

Member of the Executive Board, Head of Discovery

Jean-Philippe Rocher

Member of the Executive Board, Head of Discovery

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2019(E)

0.0K
EPS (CHF)

2019(E)

-0.420
Price To Earnings (TTM)
--
Price To Sales (TTM)
22.44
Price To Book (MRQ)
1.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.23
LT Debt To Equity (MRQ)
0.35
Return on Investment (TTM)
-30.34
Return on Equity (TTM)
-27.86

Latest News

Latest News

BRIEF-Addex Therapeutics Submits Registration Statement With US SEC

* SUBMITS REGISTRATION STATEMENT WITH U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSS REPRESENTING SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex Therapeutics Increases Issued Share Capital

* HAS INCREASED ITS CAPITAL FROM 28,564,031 TO 32,848,635 THROUGH THE ISSUE OF 4,284,604 NEW REGISTERED SHARES

BRIEF-Addex Therapeutics FY Net Loss At CHF 1.6 Mln

* NET LOSS FOR 2018 WAS CHF1.6 MILLION COMPARED TO CHF3.2 MILLION FOR 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

CORRECTED-BRIEF-Addex Therapeutics FY Oper Income Up At CHF 6.8 Mln

* FY NET CASH FROM OPERATING ACTIVITIES OF CHF1.9 MILLION (2017: CHF1.2 MILLION)

BRIEF-Addex And Indivior To Accelerate Additional GABAB PAM Compounds For Addiction

* ADDEX AND INDIVIOR TO ACCELERATE ADDITIONAL GABAB PAM COMPOUNDS FOR ADDICTION AS INDIVIOR ELECTS TO STOP DEVELOPMENT OF ADX71441 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex Therapeutics H1 Net Income At CHF 2.4 Million

* COMPLETED FIRST HALF 2018 WITH CHF43.6 MILLION IN CASH AND CASH EQUIVALENTS

BRIEF-Addex ADX10061 Receives £1.2 Million Funding From The Wellcome Trust

* REG-ADDEX ADX10061 RECEIVES £1.2 MILLION FUNDING FOR MANUFACTURE AND INVESTIGATOR LED CLINICAL STUDIES AS PART OF THE TOOLS FOR HUMAN DRUG AND BRAIN RESEARCH (THUNDR2) INITIATIVE FROM THE WELLCOME TRUST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex: Selective mGlu2 PAM ADX71149 Shows Promise In Treating Severe Panic Disorders And PTSD

* ADDEX’S SELECTIVE MGLU2 PAM ADX71149 SHOWS PROMISE IN TREATING SEVERE PANIC DISORDERS AND PTSD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex Therapeutics FY Net Loss At CHF 3.3 Million

* NET LOSS FOR 2017 FINANCIAL YEAR WAS CHF3.3 MILLION COMPARED TO CHF3.1 MILLION FOR 2016

BRIEF-Addex Therapeutics Launches CHF 40 Mln Capital Increase

* LAUNCHES CHF40 MILLION CAPITAL INCREASE WITH COMMITMENT FROM SPECIALIST US HEALTHCARE INVESTORS

BRIEF-Addex Therapeutics: Cash Position Of CHF 6.5 Mln As Of Jan. 31, 2018

* CASH POSITION OF CHF6.5 MILLION AS OF 31 JANUARY 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex and Indivior Sign Strategic Partnership

* REG-ADDEX AND INDIVIOR SIGN STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF GABAB PAMS AS ADDICTION TREATMENTS

BRIEF-Addex receives $5.3 mln grant from US National Institute on Drug Abuse for ADX71441

* REG-ADDEX THERAPEUTICS ADX71441 PROGRAM AWARDED $5.3 MILLION GRANT FROM US NATIONAL INSTITUTE ON DRUG ABUSE TO SUPPORT HUMAN STUDIES FOR THE TREATMENT OF COCAINE USE DISORDER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex Therapeutics H1 net loss widens to CHF 1.8 million

* NET LOSS INCREASED TO CHF1.8 MILLION IN THE FIRST HALF OF 2017 FROM CHF1.5 MILLION IN THE FIRST HALF OF 2016

BRIEF-Addex Therapeutics FY2016 net loss shrinks to CHF 3.1 mln

* FY net loss for the year decreased significantly to 3.1 million Swiss francs ($3.09 million)for 2016, compared to 4.2 million Swiss francs for 2015

BRIEF-Addex Therapeutics FY cash and cash equivalents of CHF 1.4 mln

* Raises 3.0 million Swiss francs ($2.98 million) through private placement of treasury shares and extends cash runway through 2018

BRIEF-Addex: awarded $835,000 grant from Michael J. Fox foundation

* Addex awarded $835,000 grant from Michael J. Fox foundation to advance TrkB pams for treatment of Parkinson's Disease Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex ADX71441 demonstrates significant efficacy in highly translational preclinical model of chronic osteoarthritis pain

* Addex ADX71441 demonstrates statistically significant efficacy in a highly translational preclinical model of chronic osteoarthritis pain Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Addex Therapeutics appoints Roger G. Mills as Chief Medical Officer

* Says Addex appoints biopharmaceutical industry veteran, Roger G. Mills, M.D., as Chief Medical Officer Source text - http://bit.ly/2gNzjj5 Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up